Revolutionizing Localized Lung Cancer Treatment: Neoadjuvant Chemotherapy plus Immunotherapy for All?

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Research

Background:

• Resectable non-small cell lung cancer (NSCLC) presents a significant challenge, with high mortality rates even after surgery.
• Current treatments like perioperative chemotherapy offer limited survival benefits for many early-stage lung cancer patients.
• Novel therapeutic strategies are urgently needed to improve outcomes in resectable NSCLC.

Purpose of the Study:

• To review the efficacy of combining chemotherapy and immunotherapy for resectable non-small cell lung cancer (NSCLC).
• To evaluate the impact of neoadjuvant chemoimmunotherapy on surgical procedures and patient quality of life.
• To identify challenges and future directions for integrating combination therapy in NSCLC management.

Main Methods:

• Systematic review of existing studies on neoadjuvant chemotherapy and immunotherapy in resectable NSCLC.
• Analysis of data regarding treatment response, surgical outcomes, and patient-reported quality of life.
• Exploration of challenges, including predictive biomarker identification and treatment resistance.

Main Results:

• Combination therapy demonstrates potential benefits in improving survival and pathologic complete response (pCR) rates.
• Impact on surgical procedures and patient quality of life requires further investigation.
• Challenges remain for specific patient subgroups, including those with stage II disease or specific mutations, and in identifying predictive biomarkers.

Conclusions:

• Neoadjuvant chemoimmunotherapy represents a promising new paradigm for resectable NSCLC.
• Further research is needed to optimize treatment strategies and overcome existing challenges.
• Personalized treatment approaches incorporating immunotherapy and chemotherapy are crucial for enhancing patient survival and outcomes.